



July 31, 2025

Press Release

Eiken Chemical Co., Ltd.
 Representative: Yuji Segawa,
 President & CEO
 Securities code: 4549 (TSE Prime Market)

**(Update on Disclosed Matter) Notice Concerning Transfer of Equity Interests of a Consolidated
 Subsidiary and Recording of Extraordinary Income**

We have executed the Transfer Agreement of Equity Interests regarding the matter disclosed in the “Notice Concerning Transfer of Equity Interests of Consolidated Subsidiaries” dated May 13, 2025, and hereby announce the details as follows.

1. Overview of the Consolidated Subsidiary

(1)	Company name	EIKEN CHINA CO., LTD.	
(2)	Company Address	1058 Ha Lei Road, Zhangjiang Hi-Tech Park, Pudong new District, Shanghai, P.R.C.	
(3)	Representative	Chairperson Yasuyoshi Mori	
(4)	Business	Manufacturing and sales of clinical diagnostics	
(5)	Capital	12.05 million US dollars	
(6)	Date founded	September 24, 2004	
(7)	Equity ratio	Our company 100%	
(8)	Relationship between our company and the company	capital relationship	Our company holds a 100% equity interest in the subsidiary concerned.
		human relationship	Officers and employees of our company concurrently serve as officers of the subsidiary concerned.
		business relationship	The subsidiary concerned processes and produces our clinical diagnostics, and also engages in the procurement, manufacturing, and sales of our clinical diagnostics.
(9)	Business performance and financial position of the company in the last three years		
	Period	Fiscal year ended March 2023	Fiscal year ended March 2024
			Fiscal year ended March 2025
	Net assets	1,116 million yen	1,177 million yen
	Total assets	1,168 million yen	1,216 million yen
	Net sales	487 million yen	469 million yen
	Operating profit	(76) million yen	(47) million yen
	Ordinary profit	(52) million yen	(20) million yen
	Net profit	(52) million yen	(20) million yen
			(295) million yen

2 . Reason for Transfer of Equity Interest

As part of our ongoing review of the product portfolio, we have determined that transferring the raw materials processing currently conducted at EIKEN CHINA CO., LTD. (Hereinafter, "Eiken China") to our Nogi Factory will lead to improved production efficiency. Furthermore, by switching from indirect sales through Eiken China to direct sales of our products, we expect to enhance management efficiency. Based on these considerations, we have concluded that the transfer of our equity interest in Eiken China will contribute to the enhancement of our company's corporate value.

3 . Overview of Transferee

Regarding the transferee, although it is only one Chinese corporation, we refrain from disclosing its name due to confidentiality considerations with the transferee. Please note that there is no capital relationship, human relationship, or ongoing business relationship between our company and its consolidated subsidiary and the transferee, and the transferee does not fall under the category of related parties.

4 . Overview of Transfer of Equity Interest

(1) Percentage of equity interest before the transfer	100%
(2) Percentage of equity interest to be transferred	100%
(3) Percentage of equity interest after the transfer	0%

Note: Although the transfer price is not disclosed due to confidentiality considerations with the transferee, it has been determined through a fair process and mutual discussions and is recognized as fair and appropriate by our company.

5 . Schedule of Transfer of Equity Interest

(1) Date of resolution at the Board of Directors' Meeting	May 13, 2025
(2) Date of execution of the Transfer Agreement	July 31, 2025
(3) Date of transfer of equity interests	September 2025 (planned)

6 . Future Prospects

As a result of this equity transfer, Eiken China will be excluded from our consolidated subsidiaries. Furthermore, the gain on sales of shares of the subsidiary arising from this transfer of equity interest is expected to be recorded as extraordinary income in the fiscal year ending March 2026, approximately 1,100 million yen in non-consolidated financial statements and approximately 1,900 million yen in consolidated financial statements. This financial impact has already been incorporated into our earnings forecast for the fiscal year ending March 2026.

End